2018-02-05T09:03:40-06:00 2017-03-31 521511275 RAFFA PC 1899 L STREET NW SUITE 850 WASHINGTON DC 20036 990 2016-04-01 760514428 MELANOMA RESEARCH FOUNDATION MELA 8006731290 1411 K STREET NW NO 800 WASHINGTON DC 20005 STEVE SILVERSTEIN CHAIR 8006731290 2018-02-05 1 FRANK H SMITH P00639053 2028225000 2018-02-05 207.238.152.31 2018-02-05 10:03:23 ES P 248DEB9EEDB6BAD9CF18FF838D0EF823C1BE4C2C 1A0AE8A7BB8C6D2397DB88F111DB3F763BC2E0F7 2016 2021-01-29 14:40:06Z STEVE SILVERSTEIN 1411 K STREET NW NO 800 WASHINGTON DC 20005 5748216 0 X WWW.MELANOMA.ORG X 1996 TX FUND RESEARCH FOR A CURE, EDUCATE/RAISE AWARENESS & ACT AS AN ADVOCATE FOR MELANOMA COMMUNITY. 16 15 24 1000 0 0 5736841 5651905 12500 0 84 -225 -135438 -94443 5613987 5557237 1327525 1409500 0 0 1717780 1751149 235344 177180 535720 2459779 2680612 5740428 6018441 -126441 -461204 1152441 885237 2080513 2274332 -928072 -1389095 X THE MELANOMA RESEARCH FOUNDATION (MRF)SUPPORTS MEDICAL RESEARCH FOR FINDING EFFECTIVE TREATMENTS AND EVENTUALLY A CURE FOR MELANOMA; EDUCATES PATIENTS AND PHYSICIANS ABOUT DIAGNOSIS AND TREATMENT OF MELANOMA; AND ACTS AS AN ADVOCATE FOR THE MELANOMA COMMUNITY TO RAISE THE AWARENESS OF THIS CANCER. 0 0 2238052 1409500 RESEARCH - TO FUND MELANOMA RESEARCH AND SUPPORT DOCTORS AND RESEARCHERS WHO ARE WORKING TO FIND A CURE FOR THIS DEADLY SKIN CANCER. CURRENTLY, MRF FUNDS FIRST AND SECOND-YEAR CAREER DEVELOPMENT AWARDS, FIRST AND SECOND-YEAR ESTABLISHED INVESTIGATOR AWARDS, AND MEDICAL STUDENT AWARDS IN DERMATOLOGY. 1709555 EDUCATION - MRF BELIEVES THAT PATIENTS WHO ARE WELL-INFORMED AND WELL-SUPPORTED LIVE LONGER AND BETTER. MRF PROVIDES LIVE PATIENT SYMPOSIA LED BY MELANOMA EXPERTS, HOSTS THE LARGEST ONLINE COMMUNITY OF MELANOMA PATIENTS IN THE WORLD, OFFERS A TOLL-FREE HELP LINE FOR PATIENTS AND FAMILIES, RUNS A STATE-OF THE-ART CLINICAL TRIALS FINDER AND PROVIDES A WIDE ARRAY OF PRINT AND ONLINE EDUCATIONAL MATERIALS. 1214626 ADVOCACY - MRF IS DEDICATED TO RAISING AWARENESS OF MELANOMA WITH THE GOAL OF PROMOTING BOTH PRIMARY PREVENTION AND EARLY DETECTION. WORKING WITH A LARGE AND GROWING NETWORK OF GRASSROOTS VOLUNTEERS AND HIGH-PROFILE STRATEGIC PARTNERS, MRF IS ACTIVELY ENGAGED IN COMBATING THE RISING INCIDENCE OF MELANOMA. IN 2011, THE MRF BEGAN RAISING AWARENESS AND FUNDS FOR OCULAR MELANOMA THROUGH ITS CURE OM (THE COMMUNITY UNITED FOR RESEARCH AND EDUCATION OF OCULAR MELANOMA) INITIATIVE. 5162233 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 0 1 0 0 0 0 0 1 1 0 0 1 0 1 0 0 0 0 0 0 0 1 0 0 0 0 0 1 1 1 0 0 1 63 0 1 24 1 0 0 0 0 0 1 1 0 0 0 0 X 16 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 AL AK AZ AR CA CO CT FL GA HI IL KS KY MA MD ME MI MN MS NC ND NH NJ NM NY OH OK OR PA RI UT VA WA WI WV TN SC X STEVE SILVERSTEIN 8006731290 1411 K STREET NW NO 800 WASHINGTON DC 20005 STEVE SILVERSTEIN CHAIR 2.00 1.00 X X 0 0 0 JEFFREY HARRIS VICE CHAIR 2.00 X X 0 0 0 GEORGE P JAMESON TREASURER 2.00 X X 0 0 0 JOE FAZIO SECRETARY 2.00 X X 0 0 0 STAN ADLER BOARD MEMBER 1.00 X 0 0 0 CARL AMDAHL BOARD MEMBER 1.00 X 0 0 0 MICHAEL B ATKINS MD BOARD MEMBER 1.00 1.00 X 0 0 0 REBECCA K DREMAN BOARD MEMBER 1.00 X 0 0 0 TUCKER ESKEW BOARD MEMBER 1.00 X 0 0 0 ANTHONY T HENDRICKSON BOARD MEMBER 1.00 1.00 X 0 0 0 RANDY LOMAX MA MFT BOARD MEMBER - UNTIL 07/2016 1.00 1.00 X 0 0 0 CHAD MACDONALD BOARD MEMBER 1.00 X 0 0 0 ALISON MARTIN BOARD MEMBER 1.00 X 0 0 0 WILLIAM G REILLY BOARD MEMBER 1.00 X 0 0 0 ZE'EV A RONAI PHD BOARD MEMBER 1.00 1.00 X 0 0 0 CHERYL STRATOS BOARD MEMBER 1.00 X 0 0 0 MARK WEINZIERL BOARD MEMBER 1.00 X 0 0 0 TIMOTHY TURNHAM PHD EXECUTIVE DIRECTOR - UNTIL 02/2017 40.00 X 181844 0 17457 SUSAN M DORSEY CPA CONTROLLER 40.00 X 107073 0 5049 288917 0 22506 2 0 1 0 J & R GRAPHICS 155 WEBSTER STREET UNIT L HANOVER MA 02339 PRINTING SERVICES 359258 JONES PUBLIC AFFAIRS 1420 K STREET NW SUITE 1050 WASHINGTON DC 20005 COMMUNICATIONS 218863 POWERED BY PROFESSIONALS 1460 BROADWAY NEW YORK NY 10026 FUNDRAISING SERVICES 135547 3 93153 1323566 4235186 5651905 29 29 6457 6711 -254 -254 -254 81673 1323566 184268 -102595 -102595 OTHER 900099 7249 7249 MERCHANDISE 452000 903 903 8152 5557237 0 0 -94668 1409500 1409500 230669 69201 115335 46133 1269490 1099689 28234 141567 30823 25742 1650 3431 114747 98349 3282 13116 105420 82824 9512 13084 22484 22484 102809 99535 3274 108242 108242 177180 177180 582872 562809 20063 15514 11723 2108 1683 592452 485660 35253 71539 195033 147377 26504 21152 102486 80099 10593 11794 302798 265253 10700 26845 423797 421146 2651 20145 15745 2082 2318 22802 17102 5700 RECOGNITION/AWARDS 99046 99046 RECRUITMENT 44301 33226 11075 MEMBERSHIP DUES 21199 15899 5300 STAFF DEVELOPMENT 18754 14066 4688 5878 5878 6018441 5162233 320488 535720 233917 171344 75207 3003 579241 434358 140847 172662 384172 357644 42223 26528 8934 15768 72072 61574 1152441 885237 381880 487390 1472916 1522916 225717 264026 2080513 2274332 X -2095773 -2419008 1167701 1029913 -928072 -1389095 1152441 885237 -461204 181 0 X 0 1 X 1 0 X 4874503 5729925 385408 5736841 5651905 22378582 4874503 5729925 385408 5736841 5651905 22378582 1089257 21289325 4903 16905 68 145 29 22050 45000 58764 3989 7249 115002 22515634 461347 0.94550 0.94960 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER - 2012 AMOUNT: $ 45,000. 2013 AMOUNT: $ 58,764. 2014 AMOUNT: $ 0. 2015 AMOUNT: $ 3,989. 2016 AMOUNT: $ 7,249. SCHEDULE A, PART II, COLUMN (D): DUE TO A CHANGE IN ACCOUNTING PERIOD, MRF FILED A 2015 SHORT YEAR RETURN FOR THE PERIOD OF JANUARY 1, 2015 TO MARCH 31, 2015 WHICH IS REFLECTED IN THE 2014 COLUMN. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 1 0 1 5000 0 0 1 3298 1 39754 1 60190 108242 0 PART II-B, LINE 1: A LOBBYING FIRM WAS RETAINED TO ASSIST MRF IN DEVELOPING, COORDINATING AND IMPLEMENTING A FEDERAL ADVOCACY PLAN TO INCREASE AWARENESS OF SKIN CANCER PREVENTION AND MELANOMA, AND TO INCREASE FEDERAL FUNDING FOR SKIN CANCER PREVENTION AND MELANOMA RESEARCH AT THE DEPARTMENTS OF HEALTH AND HUMAN SERVICES, DEFENSE, THE ENVIRONMENTAL PROTECTION AGENCY, AND OTHER RELEVANT AGENCIES. 5690 3654 2036 347994 334040 13954 30488 19950 10538 26528 EVENT DEPOSITS 61574 61574 DEFERRED RENT 11789 DUE TO AFFILIATE 252237 264026 X PART X, LINE 2: MRF PERFORMED AN EVALUATION OF UNCERTAIN IN INCOME TAXES FOR THE YEAR ENDED MARCH 31, 2017, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS. X X X X X X 1 POWERED BY PROFESSIONALS 1375 BROADWAY NEW YORK NY 10018 NEW YORK GALA 0 921366 120597 800769 POWERED BY PROFESSIONALS 1375 BROADWAY NEW YORK NY 10018 DENVER GALA 0 187169 22750 164419 GLATZ MANAGEMENT SERVICES 19244 S BLACKHAWK PARKWAY MOKENA IL 60448 CHICAGO GALA 0 120495 20000 100495 TVD ASSOCIATES 405 NORTH STANWICK ROAD MOORESTOWN NJ 08057 PHILADELPHIA 0 98815 11333 87482 1327845 174680 1153165 AK AL AR AZ CA CO CT FL GA HI IL KS KY NC ND NH NJ NM NY OH OK OR PA RI SC TN UT VA WA WI WV ME MD MS MA MI MN DC GALA - NEW YORK 921366 883297 38069 33774 64571 2877 GALA - DENVER 187169 176474 10695 5995 10091 3 296704 263795 32909 26827 38483 1650 1405239 1323566 81673 66596 113145 4527 184268 -102595 1 GEORGE WASHINGTON UNIVERSITY 2121 EYE STREET NW ROOM 601 WASHINGTON DC 20052 530196584 501(C)(3) 500000 TO SUPPORT RESEARCH FOR MELANOMA CANCER THOMAS JEFFERSON UNIVERSITY 125 S 9TH STREET SHERIDAN BUILDING PHILADELPHIA PA 19107 231352651 501(C)(3) 200000 TO SUPPORT RESEARCH FOR MELANOMA CANCER YALE UNIVERSITY 47 COLLEGE STREET SUITE 203 NEW HAVEN CT 06520 060646973 501(C)(3) 200000 TO SUPPORT RESEARCH FOR MELANOMA CANCER UNIVERSITY OF COLORADO PO BOX 910238 DENVER CO 80291 846000555 501(C)(3) 75000 TO SUPPORT RESEARCH FOR MELANOMA CANCER UNIVERSITY OF UTAH 75 S 2000 E SALT LAKE CITY UT 84112 876000525 501(C)(3) 100000 TO SUPPORT RESEARCH FOR MELANOMA CANCER UNIVERSITY OF TX-MD ANDERSON CENTER 1515 HOLCOMBE BOULEVARD HOUSTON TX 77030 746001118 501(C)(3) 100000 TO SUPPORT RESEARCH FOR MELANOMA CANCER MELANOMA RESEARCH FOUNDATION BREAKTHROUGH CONSORTIUM INC 1411 K STREET NW SUITE 800 WASHINGTON DC 20005 800671049 501(C)(3) 209500 TO SUPPORT RESEARCH FOR MELANOMA CANCER SOCIETY FOR MELANOMA RESEARCH PO BOX 113 CLIFTON PARK NY 12065 810638484 501(C)(3) 10000 TO SUPPORT RESEARCH FOR MELANOMA CANCER 8 0 PART I, LINE 2: THE SCIENTIFIC ADVISORY COMMITTEE OF THE MRF CLOSELY MONITORS GRANT FUND USAGE. PHYSICIANS AND SCIENTISTS FROM WORLD-RENOWNED EDUCATIONAL AND RESEARCH INSTITUTIONS MAKE UP THE ADVISORY MEMBERSHIP. FINANCIAL AND SCIENTIFIC PROGRESS REPORTS ARE SUBMITTED TO THE MRF AFTER THE FIRST YEAR OF THE GRANTING PERIOD. FULL FINANCIAL AND SCIENTIFIC REPORTS DETAILING ALL ACTIVITIES DURING THE GRANTING PERIOD ARE SUBMITTED WITHIN 60 DAYS OF THE END OF THE GRANTING PERIOD (EVEN IF A NO-COST EXTENSION IS REQUESTED). ACKNOWLEDGEMENT OF SUPPORT FROM THE MRF IS INCLUDED IN ANY PUBLISHED REPORT PERTAINING TO FINDINGS RESULTING FROM RESEARCH CONDUCTED UNDER THE GRANT AWARD. X X X 0 0 0 0 0 0 0 0 0 TIMOTHY TURNHAM PHD EXECUTIVE DIRECTOR - UNTIL 02/2017 181844 0 0 0 0 0 5200 0 12257 0 199301 0 0 0 STAN ADLER ASSOCIATES STAN ADLER, BOARD MEMBER, IS ALSO THE CHAIR AND FOUNDER OF THE ASSOCIATES 72000 MRF PAID A RETAINER FEE TO THE ASSOCIATES FOR GRAPHIC DESIGN AND MARKETING SERVICES. 0 FORM 990, PART VI, SECTION B, LINE 11B THE CONTROLLER AND THE EXECUTIVE DIRECTOR REVIEW THE FEDERAL FORM 990 PREPARED BY AN INDEPENDENT ACCOUNTING FIRM. UPON SUBMISSION OF THE FINAL DRAFT, THE FORM 990 IS DISTRIBUTED TO THE BOARD OF DIRECTORS AND THE FINANCE COMMITTEE FOR THEIR REVIEW PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE CONFLICT OF INTEREST POLICY IS DISTRIBUTED ANNUALLY TO ALL MEMBERS OF THE BOARD OF DIRECTORS, KEY PERSONNEL, AND COMMITTEE MEMBERS. EACH RECIPIENT OF THE POLICY RETURNS A SIGNED AND DATED RESPONSE FORM INDICATING THEY REVIEWED THE POLICY WHILE NOTING IF ANY CONFLICTS EXIST. FOLLOWING THE FULL DISCLOSURE OF A POSSIBLE CONFLICT OF INTEREST DURING THE YEAR, THE BOARD OF DIRECTORS WILL DETERMINE WHETHER A CONFLICT OF INTEREST EXISTS AND THE BOARD MEMBER WITH THE POSSIBLE CONFLICT WILL RECUSE HIMSELF OR HERSELF FROM THE DISCUSSION AND VOTE. FORM 990, PART VI, SECTION B, LINE 15A COMPENSATION FOR THE EXECUTIVE DIRECTOR IS DETERMINED IN THE EXECUTIVE SESSION OF A BOARD OF DIRECTORS MEETING AND IS BASED UPON COMPARABLE SALARY DATA. THE BOARD OF DIRECTORS CONVENES AN AD HOC COMPENSATION COMMITTEE THAT CONTRACTED WITH AN OUTSIDE EXPERT IN SALARY EVALUATION. THIS OUTSIDE GROUP LOOKS AT THE SALARIES OF ALL MRF MANAGEMENT AND COMPARES THOSE SALARIES WITH INDUSTRY STANDARDS, ADJUSTED FOR REGIONAL VARIATIONS. APPROPRIATE ADJUSTMENTS ARE MADE TO ENSURE THAT MRF SALARIES ARE IN KEEPING WITH BEST PRACTICES. THE LAST COMPENSATION REVIEW FOR THE EXECUTIVE DIRECTOR WAS CONDUCTED IN THE FALL OF 2015. FORM 990, PART VI, SECTION C, LINE 19 MRF'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST. MELANOMA RESEARCH FOUNDATION BREAKTHROUGH CONSORTIUM INC 1411 K STREET SUITE 800 WASHINGTON DC 20005 800671049 TO ORGANIZE, CONDUCT, AND SUPPORT CLINICAL TRIALS DC 501(C)(3) LINE 12A, I MELANOMA RESEARCH FOUNDATION 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 MELANOMA RESEARCH FOUNDATION BREAKTHROUGH CONSORTIUM INC B 209500 COST